ES2200080T3 - Derivados de quinolina que tienen propiedades antagonistas de neuroquininas 3. - Google Patents
Derivados de quinolina que tienen propiedades antagonistas de neuroquininas 3.Info
- Publication number
- ES2200080T3 ES2200080T3 ES96939926T ES96939926T ES2200080T3 ES 2200080 T3 ES2200080 T3 ES 2200080T3 ES 96939926 T ES96939926 T ES 96939926T ES 96939926 T ES96939926 T ES 96939926T ES 2200080 T3 ES2200080 T3 ES 2200080T3
- Authority
- ES
- Spain
- Prior art keywords
- diseases
- disorders
- rent
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9524104.8A GB9524104D0 (en) | 1995-11-24 | 1995-11-24 | Novel compounds |
| GB9524104 | 1995-11-24 | ||
| PCT/EP1996/005209 WO1997019927A1 (en) | 1995-11-24 | 1996-11-22 | Quinoline derivatives as nk3 antagonists |
| CA002238171A CA2238171C (en) | 1995-11-24 | 1998-05-21 | Quinoline derivatives as nk3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2200080T3 true ES2200080T3 (es) | 2004-03-01 |
Family
ID=31496493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96939926T Expired - Lifetime ES2200080T3 (es) | 1995-11-24 | 1996-11-22 | Derivados de quinolina que tienen propiedades antagonistas de neuroquininas 3. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6743804B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0874827B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2000512614A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2238171C (cg-RX-API-DMAC7.html) |
| CY (1) | CY2505B1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69628334T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2200080T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB9524104D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1997019927A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037922B1 (en) | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
| ATE247652T1 (de) | 1999-03-29 | 2003-09-15 | Neurogen Corp | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
| ES2248084T3 (es) | 1999-06-14 | 2006-03-16 | Eli Lilly And Company | Inhibidores de serinproteasa. |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP3822494B2 (ja) | 1999-10-19 | 2006-09-20 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| WO2002032861A2 (en) | 2000-10-17 | 2002-04-25 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| GB0028964D0 (en) * | 2000-11-28 | 2001-01-10 | Smithkline Beecham Spa | Novel compounds |
| AU2002361577A1 (en) | 2001-10-30 | 2003-05-12 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| WO2004002484A1 (ja) * | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | ホスホジエステラーゼ阻害剤 |
| DE602004028678D1 (de) | 2003-01-28 | 2010-09-23 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| RU2229475C1 (ru) * | 2003-03-06 | 2004-05-27 | ООО "Исследовательский институт химического разнообразия | 6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека |
| TW200804288A (en) | 2005-12-12 | 2008-01-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| WO2008154207A1 (en) * | 2007-06-08 | 2008-12-18 | The Burnham Institute For Medical Research | Methods and compounds for regulating apoptosis |
| CA2930674A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| KR20220042487A (ko) | 2008-12-31 | 2022-04-05 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법 |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| JP6392754B2 (ja) | 2012-08-21 | 2018-09-19 | アーデリクス，インコーポレーテッド | 体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるｎｈｅ仲介の逆輸送を阻害するための化合物並びに方法 |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| BR112015025805A2 (pt) | 2013-04-12 | 2017-07-25 | Ardelyx Inc | compostos de ligação de nh3 e métodos para inibir o transporte de fosfato |
| WO2014170648A1 (en) | 2013-04-19 | 2014-10-23 | Astrazeneca Ab | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| ES2726927T3 (es) * | 2014-07-08 | 2019-10-10 | Dow Agrosciences Llc | Proceso para la preparación de ácidos 3-hidroxipicolínicos |
| WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
| WO2018129552A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| BR112019013963A2 (pt) | 2017-01-09 | 2020-04-28 | Ardelyx Inc | inibidores de antiporte mediado por nhe |
| JPWO2020101017A1 (ja) * | 2018-11-15 | 2021-09-30 | 国立大学法人九州大学 | Ｉｌ−３１介在性疾患の予防又は治療剤及び医薬組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2538388B1 (fr) * | 1982-12-24 | 1985-06-21 | Pharmuka Lab | Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments |
| EP0919245A3 (en) * | 1991-09-20 | 2000-11-15 | Glaxo Group Limited | NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis |
| EP0585913B1 (en) * | 1992-09-04 | 1997-12-29 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
| TW263498B (cg-RX-API-DMAC7.html) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| DE69531458T2 (de) * | 1994-05-27 | 2004-08-05 | Glaxosmithkline S.P.A. | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
| IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
-
1995
- 1995-11-24 GB GBGB9524104.8A patent/GB9524104D0/en active Pending
-
1996
- 1996-11-22 DE DE69628334T patent/DE69628334T2/de not_active Expired - Lifetime
- 1996-11-22 JP JP09520159A patent/JP2000512614A/ja not_active Ceased
- 1996-11-22 ES ES96939926T patent/ES2200080T3/es not_active Expired - Lifetime
- 1996-11-22 WO PCT/EP1996/005209 patent/WO1997019927A1/en not_active Ceased
- 1996-11-22 EP EP96939926A patent/EP0874827B1/en not_active Expired - Lifetime
-
1998
- 1998-05-21 CA CA002238171A patent/CA2238171C/en not_active Expired - Fee Related
-
2002
- 2002-05-07 US US10/140,452 patent/US6743804B2/en not_active Expired - Fee Related
-
2004
- 2004-11-22 CY CY0400083A patent/CY2505B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000512614A (ja) | 2000-09-26 |
| DE69628334T2 (de) | 2004-02-19 |
| CA2238171A1 (en) | 1999-11-21 |
| CA2238171C (en) | 2008-07-22 |
| US20030195204A1 (en) | 2003-10-16 |
| CY2505B1 (en) | 2005-12-23 |
| EP0874827A1 (en) | 1998-11-04 |
| DE69628334D1 (de) | 2003-06-26 |
| WO1997019927A1 (en) | 1997-06-05 |
| EP0874827B1 (en) | 2003-05-21 |
| US6743804B2 (en) | 2004-06-01 |
| GB9524104D0 (en) | 1996-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2200080T3 (es) | Derivados de quinolina que tienen propiedades antagonistas de neuroquininas 3. | |
| ES2227769T3 (es) | Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina. | |
| ES2236757T3 (es) | Derivados de quinolina. | |
| WO1997021680A9 (en) | Quinoline derivatives | |
| ES2201509T3 (es) | Derivados de quinolina-4-carboxamida como antagonista de los receptores nk-2 y nk-3. | |
| ES2254688T3 (es) | Derivados de quinolina-4-carboxamida como antagonistas de los receptores nk-3 y nk-2. | |
| EP0876348B1 (en) | Salts of quinoline derivatives as nk3 antagonists | |
| RU2155754C2 (ru) | Производные хинолина как антагонисты nk3-рецептора тахикинина | |
| CA2257662C (en) | Quinoline derivatives as tachykinin nk3 receptor antagonists | |
| AU757836B2 (en) | Quinoline derivatives | |
| AU1031797A (en) | Quinoline derivatives | |
| NZ500371A (en) | NK-2/NK-3 antagonists and their use in treating respiratory disease | |
| HK1003884B (en) | Quinoline derivatives as tachykinin nk3 receptor antagonists | |
| HK1024469B (en) | Quinoline derivatives as tachykinin nk3 receptor antagonists |